Recent 8-K filings for ABPO

• February 20, 2026, 6:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices

  Abpro receives Nasdaq delisting notice for failing minimum equity rule; trading to suspend Feb 23

  Nasdaq Panel notified Abpro on Feb 18, 2026 that it failed to demonstrate compliance with Listing Rule 5550(b)(1) by Feb 16 deadline.

• February 11, 2026, 6:59 PM ET regulatory materiality 0.75 negative item 3.01item 5.02 ◈ Listing & Compliance Notices ×2

  Abpro receives Nasdaq delisting notices after board resignations; appoints two independent directors

  Directors Eisenberg (Jan 28) and Lee (Jan 30) resigned from board and all committees.

• January 6, 2026, 6:59 PM ET regulatory materiality 0.75 positive item 7.01item 9.01

  Abpro and Celltrion announce FDA IND clearance for lead multispecific antibody ABP-102 / CT-P72

  FDA cleared IND for ABP-102 / CT-P72, a multispecific HER2 × CD3 T-cell engager targeting HER2-positive solid tumors.

• December 15, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Abpro submits IND to FDA for phase 1 trial of ABP-102/CT-P72 in HER2+ cancers

  IND filed for ABP-102/CT-P72, a HER2×CD3 T cell engager targeting HER2-positive solid tumors.

• November 4, 2025, 6:59 PM ET other material materiality 0.70 positive item 7.01item 9.01

  Abpro/Celltrion present preclinical data for CT-P72/ABP-102 at SITC 2025; poster in top 150

  Poster selected as one of Top 150 abstracts out of >1,300 submissions at SITC 2025.

• November 4, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Abpro/Celltrion present top-ranked preclinical data for CT-P72/ABP-102 at SITC 2025

  Poster selected as Top 150 abstract out of >1,300 submissions at SITC 2025.

• November 3, 2025, 6:59 PM ET other materiality 0.60 neutral item 7.01item 9.01

  Abpro announces 1-for-30 reverse stock split effective Oct 31, 2025; trading begins Nov 3

  Reverse stock split effective 5:01 p.m. ET Oct 31; stock trades split-adjusted from Nov 3 under ticker ABP.

• October 22, 2025, 7:59 PM ET other material materiality 0.65 neutral item 5.03item 9.01 ◈ Governance Changes

  Abpro Holdings to effect 1-for-30 reverse stock split, reducing shares from 81.15M to ~2.7M

  Reverse stock split ratio 1:30, effective Oct 31, 2025 at 5:01 p.m. EDT.

• October 17, 2025, 7:59 PM ET regulatory materiality 0.80 negative item 3.01 ◈ Listing & Compliance Notices ×2

  Abpro fails to regain compliance with Nasdaq MVPHS and MVLS; hearing Oct 30

  Received Notice on Oct 14, 2025 that it did not regain MVPHS ($15M) or MVLS ($50M) compliance by Oct 7 deadline.

• October 14, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.07

  Abpro Holdings shareholders approve 1-for-30 reverse stock split at 2025 annual meeting

  Stockholders elected Ian McDonald as Class I director with 30,544,989 votes for, 8,122,953 withheld, and 10,863,999 broker non-votes.

• October 3, 2025, 7:59 PM ET regulatory materiality 0.80 negative item 3.01 ◈ Listing & Compliance Notices

  Abpro Holdings receives Nasdaq delisting notice for minimum bid price non-compliance

  180-day compliance period ended Sep 29, 2025; bid price remained below $1.00.

• April 28, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Abpro/Celltrion ABP-102/CT-P72 preclinical data at AACR 2025 shows potential best-in-class HER2 x CD3 T-cell engager

  ABP-102/CT-P72 preclinical data presented orally at AACR 2025; co-developed with Celltrion via strategic partnership.

• April 16, 2025, 7:59 PM ET regulatory materiality 0.75 negative item 3.01

  Abpro Holdings receives Nasdaq deficiency notices: MVPHS below $15M, MVLS below $50M

  Received two Nasdaq deficiency notices on April 10, 2025: MVPHS below $15M and MVLS below $50M.

• April 15, 2025, 7:59 PM ET other material materiality 0.85 negative item 4.02

  Abpro Holdings restates FY22, FY23, Q3 2024 due to $3.3M liability understatement

  Audit committee concluded prior-period financials should no longer be relied upon.

• April 8, 2025, 7:59 PM ET regulatory materiality 0.65 negative item 3.01

  Abpro Holdings receives Nasdaq minimum bid price deficiency notice; 180-day cure period.

  Received Nasdaq notice on April 2, 2025, for failure to meet $1.00 minimum bid price requirement.

• March 7, 2025, 6:59 PM ET leadership materiality 0.75 neutral item 5.02 ◈ executive_change ×2

  Abpro terminates CEO Ian Chan, appoints Miles Suk as new CEO

  Ian Chan terminated as CEO and principal executive officer, effective March 3, 2025.

• February 21, 2025, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Abpro provides pipeline update; Celltrion partnership for ABP-102 fully funded with up to $1.75B milestones

  Celltrion funds all development of ABP-102 (HER2/CD3 T-cell engager) for breast/gastric cancer; Abpro retains 50% profit share.

• December 12, 2024, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Abpro celebrates business combination close; raises $10M and secures $50M equity facility

  Business combination with ACAB closed Nov 13, 2024; Nasdaq bell ringing ceremony held Dec 12.

• December 10, 2024, 6:59 PM ET other material materiality 0.60 negative item 4.01item 9.01

  Abpro Holdings dismisses Marcum as auditor; engages Wolf & Company; cites material weaknesses

  Effective Dec 9, 2024, Abpro dismissed Marcum LLP and engaged Wolf & Company as independent auditor.

• November 26, 2024, 6:59 PM ET M&A materiality 0.85 neutral item 1.01item 2.01item 9.01item 5.02item 3.02item 2.03item 3.03item 5.01item 5.03item 5.06

  Abpro Holdings completes de-SPAC merger with Abpro Corporation; stock begins trading Nov 14

  Merger Consideration ~$500M: ~50M shares issued (39.1M to Abpro shareholders, 10.9M reserved for rollover RSUs/options).

• November 13, 2024, 6:59 PM ET M&A materiality 0.70 neutral item 7.01item 9.01

  Abpro Holdings completes SPAC merger; to trade on Nasdaq under 'ABP' starting Nov. 14

  Business combination between Abpro Corporation and Atlantic Coastal Acquisition Corp. II closed; approved by Atlantic Coastal stockholders on Nov. 7.

• November 8, 2024, 6:59 PM ET other material materiality 0.60 neutral item 5.07item 9.01

  ACAB stockholders approve all proposals for Abpro business combination; 436K shares redeemed at ~$11.28

  All 9 proposals passed with 7,587,598 votes for and 20,710 against (99.7% approval).

• November 8, 2024, 6:59 PM ET other material materiality 0.75 negative item 1.01item 8.01item 9.01

  ACAB enters forward purchase deal for up to 500K shares; 80.5% of public shares seek redemption

  Forward Purchase Agreement with YA II PN for up to 500,000 recycled shares; prepayment from trust at ~$11.28/share.

• November 6, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  ACAB enters non-redemption deal to reduce redemptions up to 124K shares before Abpro vote

  Non-redemption agreement with Sandia Investment Management LP covering up to 124,352 shares.

• November 4, 2024, 6:59 PM ET debt materiality 0.75 negative item 1.01item 2.03item 3.02item 9.01

  ACAB enters $50M equity line and $5M prepaid advance with Yorkville for post-merger financing

  $5M prepaid advance via convertible notes with 8% original issue discount; $3M at merger close, $2M after registration effective and shareholder approval.

• October 21, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01item 8.01

  Atlantic Coastal gets Nasdaq delisting notice, extends SPAC deadline to Nov 19; S-4 effective for Abpro deal

  Nasdaq delisting determination on Oct 16, 2024 for failure to meet market value of publicly held shares, round lot holders, and minimum publicly held shares requirements.

• September 4, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 7.01item 9.01

  ACAB amends Abpro merger to issue 600,601 shares to sponsor in lieu of $2M cash payment

  ACAB will issue 600,601 shares of Series A common stock to its sponsor Atlantic Coastal Management II LLC, replacing $2,000,000 of Unpaid SPAC Expenses.

• August 28, 2024, 7:59 PM ET other material materiality 0.70 positive item 1.01item 3.02item 7.01item 9.01

  ACAB enters PIPE agreements for $11.2M with Abpro Bio and Celltrion for business combination

  Abpro Bio subscribes for 622,467 shares at $10/share ($6.2M total), with $4.2M portion via loan forgiveness.

• August 6, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01

  Atlantic Coastal Acquisition Corp. II receives Nasdaq delisting notice for failing minimum 400 holders

  Received Nasdaq notice on July 31, 2024 for non-compliance with Listing Rule 5450(a) requiring minimum 400 holders of record.

• June 7, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01item 9.01

  Nasdaq notifies Atlantic Coastal Acquisition Corp II of non-compliance for late Q1 2024 filing

  Received Nasdaq notice on June 3, 2024 for failure to timely file Q1 2024 Form 10-Q (due May 15).

Executive changes

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

9 positive 14 negative 26 neutral

source · ABPO on sec.gov